Clinical trial
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome - Acute Kidney Injury
NCT05875948 is registered in ClinicalTrials.gov with River 2 Renal Corp. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome - Acute Kidney Injury
- Lead sponsor
- River 2 Renal Corp.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2023
- Completion date
- December 31, 2024
- Enrollment
- 95 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.